Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:RANI NASDAQ:SKYE NASDAQ:THAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$5.54-1.2%$5.31$3.35▼$17.94$120.77M5.11247,120 shs15,378 shsRANIRani Therapeutics$0.97+3.8%$1.05$0.39▼$3.87$119.49M0.741.05 million shs99,265 shsSKYESkye Bioscience$0.86-4.7%$0.75$0.57▼$5.75$30.07M3.03480,441 shs27,553 shsTHARTharimmune$2.98-6.9%$3.74$0.95▼$9.08$112.44M1.431.48 million shs667,079 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-4.92%+3.13%+38.61%-55.73%-47.32%RANIRani Therapeutics-3.03%+4.85%+13.87%-23.69%+11.76%SKYESkye Bioscience+5.58%+2.22%+27.24%+9.64%-50.64%THARTharimmune-0.93%+2.56%-1.54%-22.71%+107.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$5.54-1.2%$5.31$3.35▼$17.94$120.77M5.11247,120 shs15,378 shsRANIRani Therapeutics$0.97+3.8%$1.05$0.39▼$3.87$119.49M0.741.05 million shs99,265 shsSKYESkye Bioscience$0.86-4.7%$0.75$0.57▼$5.75$30.07M3.03480,441 shs27,553 shsTHARTharimmune$2.98-6.9%$3.74$0.95▼$9.08$112.44M1.431.48 million shs667,079 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-4.92%+3.13%+38.61%-55.73%-47.32%RANIRani Therapeutics-3.03%+4.85%+13.87%-23.69%+11.76%SKYESkye Bioscience+5.58%+2.22%+27.24%+9.64%-50.64%THARTharimmune-0.93%+2.56%-1.54%-22.71%+107.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 2.62Moderate Buy$22.60307.21% UpsideRANIRani Therapeutics 2.67Moderate Buy$7.80702.47% UpsideSKYESkye Bioscience 2.63Moderate Buy$9.801,039.53% UpsideTHARTharimmune 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest SKYE, THAR, RANI, and AARD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/14/2026RANIRani Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$9.004/1/2026RANIRani Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $5.003/27/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026RANIRani Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026RANIRani Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.003/24/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.003/2/2026AARDAardvark Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$18.00 ➝ $6.003/2/2026AARDAardvark Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$35.00 ➝ $21.003/2/2026AARDAardvark Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$24.00 ➝ $6.003/2/2026AARDAardvark Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$29.00 ➝ $7.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$4.90 per shareN/ARANIRani Therapeutics$1.63M73.76N/AN/A$0.34 per share2.86SKYESkye BioscienceN/AN/AN/AN/A$0.62 per shareN/ATHARTharimmuneN/AN/AN/AN/A$0.68 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$57.59M-$2.93N/AN/AN/AN/A-44.59%-41.51%N/ARANIRani Therapeutics-$29.67M-$0.59N/AN/AN/AN/A-774.04%-106.02%5/13/2026 (Estimated)SKYESkye Bioscience-$55.92M-$1.40N/AN/AN/AN/A-143.59%-119.89%N/ATHARTharimmune-$12.20M-$3.99N/AN/AN/AN/A-588.45%-264.41%6/3/2026 (Estimated)Latest SKYE, THAR, RANI, and AARD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026RANIRani Therapeutics-$0.06N/AN/AN/A$1.13 millionN/A5/7/2026Q1 2026AARDAardvark TherapeuticsN/A-$0.99N/A-$0.99N/AN/A3/26/2026Q4 2025RANIRani Therapeutics-$0.03-$0.07-$0.04-$0.07$5.00 million$1.46 million3/23/2026Q4 2025AARDAardvark Therapeutics-$0.81-$0.81N/A-$0.81N/AN/A3/10/2026Q4 2025SKYESkye Bioscience-$0.29-$0.36-$0.07-$0.36N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ATHARTharimmuneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A10.6110.61RANIRani TherapeuticsN/A4.214.21SKYESkye BioscienceN/A3.303.30THARTharimmuneN/A4.984.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/ARANIRani Therapeutics30.19%SKYESkye Bioscience21.09%THARTharimmune1.16%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/ARANIRani Therapeutics26.51%SKYESkye Bioscience4.50%THARTharimmune6.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.82 millionN/AN/ARANIRani Therapeutics110123.69 million90.90 millionOptionableSKYESkye Bioscience1135.13 million33.55 millionOptionableTHARTharimmune237.73 million35.20 millionNot OptionableSKYE, THAR, RANI, and AARD HeadlinesRecent News About These CompaniesTharimmune Highlights Canton Network Q1 Growth, Tokenomics Shift and Validator Locking in WebinarApril 25, 2026 | marketbeat.comTharimmune Rebrands as Canton Strategic Holdings, Updates TickerFebruary 18, 2026 | tipranks.comIs Canton’s price set to explode amid Tharimmune’s rebrand?February 17, 2026 | invezz.comITharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury StrategyFebruary 17, 2026 | prnewswire.comCatherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio ImpactFebruary 11, 2026 | finance.yahoo.comTharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating OfficerFebruary 6, 2026 | prnewswire.comTharimmune Elects Jill Sommers and William Wiley to Board of DirectorsFebruary 2, 2026 | prnewswire.comTharimmune Approved as Super Validator on Canton NetworkJanuary 27, 2026 | theglobeandmail.comTharimmune Announces Expanded Role as Super Validator on Canton NetworkJanuary 26, 2026 | prnewswire.comTharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On TokenizationJanuary 23, 2026 | seekingalpha.comTharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct OfferingJanuary 22, 2026 | prnewswire.comTharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered OfferingJanuary 20, 2026 | prnewswire.comTharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton NetworkDecember 18, 2025 | prnewswire.comTharimmune appoints Jacob Asbury as CFODecember 12, 2025 | msn.comTharimmune Appoints Jacob Asbury as New CFODecember 12, 2025 | tipranks.comTharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury StrategyDecember 12, 2025 | businesswire.comTharimmune files to sell 176.93M shares of common stock for holdersDecember 5, 2025 | msn.comCrypto Company Creates Bizarre DrugNovember 22, 2025 | msn.comTharimmune (NASDAQ:THAR) Shares Up 8.9% – What’s Next?November 22, 2025 | defenseworld.netDDigital Assets Firm Copper Serves as Custodian for Tharimmune, Inc. Canton Coin Treasury StrategyNovember 19, 2025 | crowdfundinsider.comCTharimmune Announces $540M Private Placement for BlockchainNovember 17, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 20263 Overlooked Nuclear Fuel Supply Chain WinnersBy Nathan Reiff | April 26, 2026U.S.-Iran Ceasefire: Short Interest Surges for This Defense ETFBy Jessica Mitacek | April 13, 2026Atomic Dividends: Big Tech's New Energy BetBy Jeffrey Neal Johnson | May 5, 2026SKYE, THAR, RANI, and AARD Company DescriptionsAardvark Therapeutics NASDAQ:AARD$5.54 -0.07 (-1.16%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Rani Therapeutics NASDAQ:RANI$0.97 +0.04 (+3.76%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.Skye Bioscience NASDAQ:SKYE$0.86 -0.04 (-4.71%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Tharimmune NASDAQ:THAR$2.98 -0.22 (-6.88%) As of 05/7/2026Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
